Eslotin 10s 5 mg film-coated tablets

The instruction for medical use of ESLOTIN medicine the Trade name Eslotin Mezhdunarodnoye the unlicensed name Dezloratadin Lekarstvennaya the Tablet form, film coated Structure 1 tablet contains active agent - dezloratadin 5 mg, excipients: calcium hydrophosphate dihydrate, starch corn, cellulose microcrystalline, talc, magnesium stearate, structure of a cover: opadr blue 85F20400 (polyvinyl alcohol, titan E171 dioxide, macrogoal, talc, indigo carmine aluminum E132 varnish). The description of the Tablet of round shape, with a biconvex surface, film coated blue color, with dividing risky on one party. Pharmacotherapeutic group Antihistaminic drugs of systemic action. Antihistaminic drugs of systemic action others. Dezloratadin the ATX R06AX27 Code the Pharmacological Pharmacokinetics Drug properties is well absorbed from digestive tract, the maximum concentration in plasma is reached approximately in 3 hours. Elimination half-life makes about 27 hours. The bioavailability is proportional to the accepted dose (in the range of doses from 5 mg to 20 mg). Does not pass through a blood-brain barrier, gets through a placental barrier and into breast milk. Eslotin's pharmacodynamics has antihistaminic, antiallergic and anti-inflammatory effect, does not cause drowsiness. At intake dezloratadin (primary active metabolite of a loratadin) peripheral histamine H1 receptors selectively block. Suppresses a cascade of cytostatic reactions: discharge of pro-inflammatory cytokines, including interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-13 (IL-13), pro-inflammatory RANTES chemokines, products of superoxidic anions the activated polymorphonuclear neutrophils, adhesion and a chemotaxis of eosinophils, an expression of molecules of adhesion, including. R-selectin, the IgE-mediated discharge of a histamine, D2 prostaglandin and C4 leukotriene. Indications - a pollinosis, allergic rhinitis - urticaria the Route of administration and Eslotin's doses accept inside irrespective of meal in a dosage 5 mg of 1 times a day. The tablet should be swallowed entirely, without chewing and to wash down with water. Side effects - increased fatigue - dryness in a mouth - photosensitivity, myalgia, fatigue, an asthenia - a headache, hallucinations, dizziness, drowsiness, insomnia - psychomotor hyperactivity, spasms, hallucinations - tachycardia, heartbeat, lengthening of QT - abdominal pains - nausea, vomiting, dyspepsia, diarrhea, an abdominal pain - increase in activity of enzymes of a liver, increase in concentration of bilirubin, hepatitis, jaundice - hyper sensitive reactions (such as anaphylaxis, huge small tortoiseshell, small tortoiseshell, asthma, angiodystrophia, rash) of the Contraindication - hypersensitivity to drug components - pregnancy and the period of a lactation - children's age up to 18 years. Medicinal interactions When studying medicinal interaction at repeated combined use of a dezloratadin with ketokonazoly, erythromycin, azithromycin, fluoxetine, Cimetidinum of clinically significant changes of concentration of a dezloratadin in plasma it is not revealed. Dezloratadin does not strengthen effect of alcohol on the central nervous system. Special instructions With care use drug at patients with a heavy renal failure. Use in pediatrics Use of drug is possible only on doctor's orders. Pregnancy and a lactation Drug is contraindicated to use at pregnancy due to the lack of clinical data on safety of use during pregnancy. Dezloratadin is allocated with breast milk therefore use during breastfeeding is contraindicated. Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms Drug can have insignificant impact on ability to drive the car and to work with other mechanisms, patients have to be informed that in rare instances, emergence of drowsiness is possible. Overdose Symptoms: strengthening of expressiveness of side reactions. Treatment: gastric lavage with the subsequent intake of activated carbon, if necessary – symptomatic therapy. The hemodialysis is inefficient. The efficiency of peritoneal dialysis is not established. The form of release and packing On 10 tablets place in blister strip packaging from a film of polyvinylchloride and aluminum foil. On 1 or 2 planimetric packs together with the instruction for medical use in the state and Russian languages place in a pack from cardboard Storage conditions to Store in the place protected from moisture at a temperature not above 25ºС. To store out of children's reach! 3 years not to apply a period of storage after an expiration date. Prescription status According to the prescription the Producer/packer UORLD of ILACh DIGNITY MEDICINE. VE TIDZh. A.Sh., TURKEY (Bagdzhylar Ilchesi, Gyuneshli, Evren Makhallesi, Dzhami Yolu Dzhad. No. 50 K. 1B Zemin 4-5-6, Istanbul) WORLD MEDICINE İLAÇ SAN. VE TIC. A.Ş., TURKEY (Bağcılar İlçesi, Güneşli, Evren Mahallesi, Cami Yolu Cad. No: 50 K. 1B of Zemin 4-5-6, İstanbul). Owner of the registration certificate UORLD of ILACh DIGNITY MEDICINE. VE TIDZh. A.Sh., TURKEY the Address of the organization in the territory of the Republic of Kazakhstan the accepting claim (offer) from consumers on quality of RK medicine, Almaty, RIN Pharm LLP Turksibsky district, Suyunbaya Ave., 222b Ph. / fax: 8 (7272) 529090 Address of the organization responsible for post-registration observation of safety of medicine of TROKA-S PHARMA LLP, Almaty, Suyunbaya Avenue 222-b Cellular ph. +7 701 786 33 98, (24-hour access). e-mail:pvpharma@worldmedicine.kz